Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M5717 chemoprophylaxis study in controlled Plasmodium falciparum sporozoite challenge
NL-OMON49971Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in malaria comparing M5717 with Placebo (2 arms). Primary endpoints: Number of participants with positive parasitemia over time, Time to parasitemia and 3 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
cabamiquine
03
Conditions
malaria
Beyond the preview
Go deeper on NL-OMON49971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49971.